https://www.selleckchem.com/products/g140.html
Recently, Vigil showed significant clinical benefit with improvement in relapse free (RFS) and overall survival (OS) in pre-planned subgroup analysis in stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type (BRCA-wt) molecular profile. Here we analyze homologous recombination (HR) status of patients enrolled in the Phase 2b VITAL study and determine clinical benefit of Vigil in HR proficient (P) patients. Patients were previously enrolled in a Phase 2b, double-blind, placebo-controlled trial. All were in complete respons
Like
Comment
Share
